345MO IBI354 (anti-HER2 antibody-drug conjugate [ADC]) in patients (pts) with advanced solid tumors and breast cancer (BC): Results from a phase I study. - Lemech, C.; Sun, Y.; Nagrial, A.; Wu, X.; Morris, M.; Ning, F.; Yang, J.; Pan, Y.; Cai, J.; Lu, P.; Zhang, T.; Qiu, F.; et al. (Annals of Oncology, 2024)